A research team supported in part by SU2C has published findings that show how we may be able to kill cancerous cells more effectively by combining drugs that work together to significantly disrupt a cancer cell’s ability to survive DNA damage. These findings are the first to show this combination drug therapy as a novel approach for treating acute myeloid leukemia (AML) and potentially, many other cancers.
Immunotherapy and precision treatment are two of the biggest trends in cancer research and treatment today. Studies published recently in the prestigious New England Journal of Medicine show that SU2C-supported researchers are at the forefront of these remarkable trends. These studies deal with immunotherapy in advanced melanoma and targeted therapy in metastatic prostate cancer.
Congratulations to Peter Jones, PhD, DSc, a member of the SU2C scientific community, who has been elected to the prestigious National Academy of Sciences! The Academy advises the government and the nation on scientific issues. An expert in epigenetics at the Van Andel Research Institute (VARI) in Grand Rapids, Michigan, Dr. Jones was co-leader of the SU2C Epigenetics Dream Team and is continuing his work as leader of the VARI-SU2C Epigenetics Dream Team. Also serving as team leader is Dr. Stephen Baylin of VARI.
We are very excited to share with you the news that several scientists and advocates associated with Stand Up To Cancer have been appointed to the new Blue Ribbon Panel that will provide scientific guidance to the cancer “moonshot” initiative headed by Vice President Joe Biden. According to an announcement today from the National Cancer Institute, the panel will serve as a working group of the existing National Cancer Advisory Board (NCAB), which is appointed by the President, and will provide scientific guidance from thought leaders in the cancer community. The panel will begin its deliberations immediately, and will deliver a report to the NCAB this summer, according to NCI.
Researchers from the SU2C-St. Baldrick’s Foundation Pediatric Cancer Dream Team found that if medulloblastoma, a brain cancer more common in children than adults, recurs after treatment, it is likely to be genetically different from the original disease. This could open new avenues for better treatment of the recurrent tumors.
Other scientists on the pediatric team demonstrated ways to improve the process through which T cells, the immune cells needed for adoptive cell therapy (the powerful immunotherapy that has saved the lives of children with leukemia), are collected and modified in the laboratory before they are returned to the patient.
Scientists with the SU2C-Prostate Cancer Foundation Dream Team have developed a “molecular classifier” for patients with metastatic prostate cancer that has become resistant to the standard hormone treatment. Based on biomarkers, the “classifier” can help identify tumors that are transitioning to a more dangerous form of the disease, potentially improving treatment and benefitting the patient.
Researchers on the SU2C-OCRF-NOCC-OCNA Ovarian Cancer Dream Team are part of a group that studied inherited risk in ovarian cancer. They found that nearly one-fifth of the ovarian cancer cases examined are associated with inherited mutations in genes such as BRCA. Armed with this knowledge, the Dream Team is preparing a trial of improved access to genetic testing and risk assessment.
More than 1.6 million high school students are estimated to use tanning beds every year, with four times as many girls as boys using indoor tanning devices, according to a Centers for Disease Control and Prevention (CDC) study.
According to the
American Academy of Dermatology, those who have been exposed to UV radiation from indoor tanning are 59 percent more likely to develop melanoma than those who have never tanned indoors.
